Skip to content
Screener

Vertex Pharmaceuticals VRTX D&A

D&A at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$102K-42.0%

Other financials

Income statement

See full
Revenue$3.3B+12.5%
Gross profit$2.8B+11.2%
Operating income$1.2B+8.3%
Net income$1.1B+6.5%
EPS (diluted)$4.31+8.0%

Balance sheet

See full
Cash & equivalents$7.9B+57.6%
Total debt$2.0B+29.5%
Total equity$20.2B+17.9%
Total assets$27.4B+14.1%

Cash flow

See full
Operating cash flow$1.4B+74.4%
CapEx$133.4M+228%
Free cash flow$1.3B+66.4%

Valuation

See full
Market cap$132.79B+38.3%
Enterprise value$126.92B+37.1%
P/E30.1×—
P/S10.6×+2.1×

Profitability

See full
Gross margin86%-0.1pp
Operating margin38%—
Net margin35%—
FCF margin30.4%+20.2pp

Returns & leverage

See full
Return on equity23.5%—
Debt / equity0.1×0.0×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Vertex Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The source filing: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →

Filed
May 5, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000875320-26-000173

FAQ

What is Vertex Pharmaceuticals's D&A?
Vertex Pharmaceuticals (VRTX) reported D&A of $55.9M in Q1 2026.
How has Vertex Pharmaceuticals's D&A changed year-over-year?
Vertex Pharmaceuticals's D&A increased by 15.5% year-over-year, from $48.4M to $55.9M.
What is the long-term trend for Vertex Pharmaceuticals's D&A?
Over 4 years (2021 to 2025), Vertex Pharmaceuticals's D&A has grown at a 13.7% compound annual growth rate (CAGR), from $125.6M to $209.8M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Ask your AI about Vertex Pharmaceuticals's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude